19:28 , Jul 3, 2018 |  BC Extra  |  Company News

Management tracks: Cigna, Novocure, Voyager

Health services company Cigna Corp. (NYSE:CI) appointed Mark McClellan to its board, effective the earlier of Dec. 1 or the close of Cigna's acquisition of Express Scripts Holding Co. (NASDAQ:ESRX). McClellan is director of the...
17:49 , Jun 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus Cell culture studies identified three cadmium-based supramolecule coordination complexes (SCCs) that could help treat methicillin-resistant Staphylococcus aureus (MRSA) infection. The three SCCs consist of hexagonal-shaped rings that incorporate 12, 18 or 24 cadmium (II)-terpyridine...
20:15 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Sunovion's PD therapy NDA gets PDUFA date

Sunovion Pharmaceuticals Inc. said FDA accepted an NDA for apomorphine sublingual film (APL-130277) to treat "off" episodes in Parkinson's disease (PD). The PDUFA date is Jan. 29, 2019. Sunovion, a unit of Sumitomo Dainippon Pharma Co....
18:10 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Boston Biomedical reports detailed data from Phase III gastric cancer trial of napabucasin

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported data from the Phase III BRIGHTER trial in 714 patients with previously treated advanced gastric or gastroesophageal junction cancer showing that second-line...
00:06 , May 5, 2018 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 11 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 3Q; (B) 12-month EPS; Source: Yahoo! Finance, Financial Times, company websites CompanyDatePre/post mkt1Q18 EPS est1Q17 EPSExpected chgMyriad Genetics...
17:58 , Apr 20, 2018 |  BC Week In Review  |  Clinical News

Intercept's Ocaliva improves fibrosis in subgroup of primary biliary cholangitis patients

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) reported data from a subgroup of 13 primary biliary cholangitis (PBC) patients with liver fibrosis or cirrhosis at baseline and who had paired liver biopsies in the Phase III POISE trial...
23:10 , Mar 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer; autoimmune disease

INDICATION: Solid tumors; Crohn’s disease; inflammatory bowel disease (IBD) In vitro, cell culture and mouse studies suggest inhibiting CDK9 and GSK3 could help treat cancer, Crohn’s disease and ulcerative colitis. Chemical synthesis and in vitro kinase...
23:08 , Mar 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture studies suggest inhibiting CDK9 could help treat castration-resistant prostate cancer (CRPC) that is resistant to BET bromodomain protein inhibitors. In a human BET inhibitor-resistant CRPC cell line, siRNA targeting CDK9 or...
20:50 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

Sumitomo's transdermal blonanserin meets in Phase III for schizophrenia

Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported top-line data from a double-blind, international Phase III trial in 580 patients with schizophrenia showing that once-daily 40 and 80 mg doses of a transdermal patch formulation of...
23:28 , Feb 26, 2018 |  BC Extra  |  Company News

Management tracks: Vertex, Basilea

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said CMO and EVP of Global Medicines Development and Medical Affairs Jeffrey Chodakewitz will retire, effective April 1. He is succeeded by Vertex SVP of Clinical Development and Medical Affairs Reshma...